Poorva Bindal to Humans
This is a "connection" page, showing publications Poorva Bindal has written about Humans.
Connection Strength
0.232
-
Bindal P, Patell R, Chiasakul T, Lauw MN, Ko A, Wang TF, Zwicker JI. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024 Jul; 22(7):2071-2080.
Score: 0.035
-
Arun Kumar S, Mishra R, Malempati SC, Bindal P. Primary cardiac large B cell lymphoma. BMJ Case Rep. 2023 Dec 26; 16(12).
Score: 0.034
-
Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR. Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma. 2023 Jul-Aug; 64(7):1340-1343.
Score: 0.032
-
Bindal P, Jalil SA, Holle LM, Clement JM. Potential role of rituximab in metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract. 2019 Sep; 25(6):1509-1511.
Score: 0.023
-
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, Bindal P, Ramanathan M, Gerber JM, Cerny J, Patel SA. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025 Apr 15; 131(8):e35846.
Score: 0.009
-
Patell R, Bindal P, Freed J, Dodge LE, Nagaraj G, LaCasce AS, Elkon J, Im A, Suzuki S, Yedavalli N, Winegarden JD, Buss MK, Schonberg MA, Braun IM, Rangachari D. A Multicenter Feasibility Study of a Novel Curriculum for Oncology Trainees Regarding Medical Cannabis. J Natl Compr Canc Netw. 2025 Mar; 23(3):82-89.
Score: 0.009
-
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. Elife. 2023 10 17; 12.
Score: 0.008
-
Andersen M, Bindal P, Michaels P, Elavalakanar P, Liegel J, Dias A, Arnason J, Patell R. Clonal myeloid disorders following CAR T-cell therapy. Ann Hematol. 2023 12; 102(12):3643-3645.
Score: 0.008
-
Koshy AG, Kim HT, Liegel J, Arnason J, Ho VT, Antin JH, Joyce R, Cutler C, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson S, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 06 15; 141(24):2932-2943.
Score: 0.008
-
Patell R, Bindal P, Dodge L, Elavalakanar P, Freed JA, Rangachari D, Buss M, Schonberg M, Braun I. Oncology Fellows' Clinical Discussions, Perceived Knowledge, and Formal Training Regarding Medical Cannabis Use: A National Survey Study. JCO Oncol Pract. 2022 11; 18(11):e1762-e1776.
Score: 0.008
-
Xu W, Piper-Vallillo AJ, Bindal P, Wischhusen J, Patel JM, Costa DB, Peters MLB. Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. Cancer Med. 2021 03; 10(5):1545-1549.
Score: 0.007
-
Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, Rangachari D, Costa DB. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open. 2021 02 01; 4(2):e2037120.
Score: 0.007
-
Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 09 10; 136(11):1342-1346.
Score: 0.007
-
Patell R, Bogue T, Bindal P, Koshy A, Merrill M, Aird WC, Bauer KA, Zwicker JI. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020 09; 18(9):2349-2357.
Score: 0.007
-
Kethireddy N, Thomas S, Bindal P, Shukla P, Hegde U. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. J Oncol Pharm Pract. 2021 Jan; 27(1):207-211.
Score: 0.007
-
Noor A, Bindal P, Ramirez M, Vredenburgh J. Chordoma: A Case Report and Review of Literature. Am J Case Rep. 2020 Jan 23; 21:e918927.
Score: 0.006
-
Mathew Thomas V, Bindal P, Ann Alexander S, McDonald K. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J Oncol Pharm Pract. 2020 Mar; 26(2):459-461.
Score: 0.006
-
McAuliffe A, Bindal P, Haley M, Vredenburgh J. Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. J Oncol Pharm Pract. 2020 Jan; 26(1):206-208.
Score: 0.006
-
Shukla P, Bindal P, Gupta A, Lohr JW, Arora P. Quiz page March 2015: unexplained kidney failure in a patient with bladder cancer. AKI secondary to metastatic infiltration of the kidneys by poorly differentiated urothelial cancer. Am J Kidney Dis. 2015 Mar; 65(3):A17-9.
Score: 0.005